Elise Wang is a Principal on the Public Structured Finance group at Deerfield and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School.

Barbara Younger is a Trading Associate at Deerfield and joined the Firm in 1995. In her role, Ms. Younger serves as the bridge between the trading team, finance team and brokers with regard to operational and trading matters. Ms. Younger holds a B.B.A. in Communications from Fordham University and is a Notary Public.

Nelson Barriocanal is a Trader at Deerfield and joined the Firm in 2010 as Director of Research for the Deerfield Institute, overseeing various aspects of the Firm’s research. He transitioned to the Trading group in 2019. Prior to joining Deerfield, Mr. Barriocanal spent over ten years with Merrill Lynch and Susquehanna International Group, working directly with healthcare investment firms to facilitate their access to liquidity and information in the equity and option markets. Mr. Barriocanal holds a B.S. in Accounting from the University of Delaware.

Terence Karnal is a Partner and Head Equity Linked and Credit Trader on the Trading group at Deerfield and joined the Firm in 2010. He provides analytical, structuring, and trading services to the Firm. Mr. Karnal started his career at BAM Capital LLC as a volatility trader and then joined TORO Trading LLC as a Partner trading equity derivatives in the healthcare sector. Mr. Karnal holds an S.B. in Finance and Economics from the Massachusetts Institute of Technology. 

Tanya Preisser is Programming and Events Manager on the Partnership and Communications team at Deerfield and joined the Firm in 2005. In her previous role as an Associate, she provided various levels of support to the Managing Partner, a Managing Director and the Biotherapeutics team at Deerfield.  Prior to Deerfield, Ms. Preisser was Vice President, Business Manager at Augusta Advisors (now Van Hedge Fund Advisors) and its Funds of Funds, where she was responsible for new business development, client management, market research for investment opportunities and management of office operations. Before Augusta Advisors, she was a Senior Manager at two different retail companies. Ms. Preisser holds a B.S. from Boston University. 

Andrew ElBardissi, M.D., is a Partner on the Medical Devices team at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

Joseph Pearlberg, M.D., Ph.D., is the Vice President of Scientific Affairs on the Biotherapeutics group at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. Pearlberg was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his Ph.D. in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He holds a B.A. in Biochemistry from the University of Pennsylvania.

Bharath Ganesan is a Principal on the Healthcare Services group at Deerfield and joined the Firm in 2018 to focus on healthcare software and services. Before Deerfield, Mr. Ganesan was a Senior Associate at JH Whitney Capital Partners. Prior to that, Mr. Ganesan was an Associate at H.I.G. Capital, a mid-market buyout fund, and before then he worked as an investment banking analyst in the mergers and acquisitions group for Bank of America Merrill Lynch. Mr. Ganesan holds a B.A. in Economics and Political Science from Vanderbilt University, where he graduated magna cum laude, and received his M.B.A. from the Wharton School of the University of Pennsylvania with a major in Health Care Management.